JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023.

新泽西州新泽西市，2023年10月16日（GLOBE NEWSWIRE）-SCYNEXIS，Inc。（纳斯达克股票代码：SCYX），一家开创创新药物以克服和预防难治性和耐药性感染的生物技术公司，今天宣布提供第二代fungerp候选SCY-247针对广泛真菌病原体的临床前数据，包括棘白菌素抗性念珠菌和曲霉菌在内，于2023年10月20日至23日在希腊雅典举行的第11届医学真菌学趋势大会（TIMM）上发表口头报告。

Oral Presentation: Title: SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against Broad-spectrum of Fungal Pathogens, and Dose-Dependent Tissue Distribution In Vivo Session: Symposium 8: Clinic meets Pharmacology: Antifungal treatmentAbstract number: S08.6Date: Saturday, October 21Time: 3:35 p.m EEST / 8:35 a.m.

口头报告：标题：SCY-247，第二代IV/口服三萜类抗真菌：对广谱真菌病原体的体外活性和体内剂量依赖性组织分布会议：研讨会8：临床会议药理学：抗真菌治疗摘要编号：S08.6日期：10月21日星期六时间：下午3:35 EEST/上午8:35。

EDTPresenting author: Mahmoud Ghannoum, Ph.D. (Ohio, United States) Location: Room MC3, Megaron Athens International Conference Center For more information, see the TIMM website here. About SCY-247 SCY-247 is a second-generation antifungal compound from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), under development as a therapeutic option for systemic fungal diseases.

EDTPresenting作者：Mahmoud Ghannoum，博士（美国俄亥俄州）地点：Megaron雅典国际会议中心MC3室了解更多信息，请参阅此处的TIMM网站。关于SCY-247 SCY-247是来自新型结构不同的葡聚糖合酶抑制剂三萜类化合物（真菌）的第二代抗真菌化合物，正在开发中作为全身性真菌疾病的治疗选择。

The fungerps represent the first new class of antifungal compounds since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility for oral and intravenous (IV) routes of administration. SCY-247 has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, and SCYNEXIS anticipates that the U.S.

自2001年以来，真菌代表了第一类新的抗真菌化合物。这些药物将葡聚糖合成酶抑制剂的公认活性与口服和静脉内（IV）给药途径的潜在灵活性相结合。SCY-247在体外和体内均表现出广谱抗真菌活性，SCYNEXIS预计美国。

Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track d.

食品和药物管理局（FDA）可以授予SCY-247合格的传染病产品（QIDP）和快速通道d。